All Stories

Charles River launches strategic review and shakes up board amid regulatory uncertainty, sliding revenue

Charles River Laboratories is initiating a strategic review and shaking up its board amid a chaotic biopharma ecosystem and declining revenues.

May 8, 2025 - 23:17
 0
Charles River launches strategic review and shakes up board amid regulatory uncertainty, sliding revenue
Charles River Laboratories is initiating a strategic review and shaking up its board amid a chaotic biopharma ecosystem and declining revenues.
Read More

Tags:

Previous Article

Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs

Next Article

CRISPR Therapeutics sees 80% fall in LDL, triglycerides after in vivo liver editing

Related Posts

FDA misses PDUFA date for Stealth’s ultra-rare disease candidate, delaying approval decision—again

FDA misses PDUFA date for Stealth’s ultra-rare disease ...

Apr 29, 2025  0

Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Tempest cuts 80% of roles

Fierce Biotech Layoff Tracker 2025: Mural lays off 90%;...

Apr 21, 2025  0

Ex-FDA leader joins new initiative designed to fight 'unfortunate reality' of vaccine landscape

Ex-FDA leader joins new initiative designed to fight 'u...

Apr 24, 2025  0